TITLE:
Usefulness of Enteral Nutritional Intake Containing Median-Chain Fatty Acids in Parkinson’s Disease Patients with Weight Loss: A Pilot Study
AUTHORS:
Makoto Shiraishi, Kenji Isahaya, Yasuhiro Hasegawa
KEYWORDS:
Parkinson’s Disease, Weight Loss, Ghrelin, Leptin
JOURNAL NAME:
Advances in Parkinson's Disease,
Vol.8 No.1,
February
28,
2019
ABSTRACT: Background:
No solution has yet been found for the nutritional issues of Parkinson’s
disease (PD) patients with weight loss, which affects their prognosis. The objective of the present study was to
investigate whether a defined-formula diet rich in ω3 fatty
acids improved nutrition through the effect of ghrelin in PD patients with weight loss. Method:
Weight, serum total protein, albumin, lipids, serum ghrelin, serum acylghrelin,
leptin, and the Unified Parkinson’s Disease Rating Scale were monitored for
approximately 3 months in 11 subjects given a defined-formula diet rich in ω3 fatty
acids for 3 months and 5 control subjects who received no such treatment.
Results: No significant changes from baseline in serum ghrelin, acylghrelin,
and leptin levels were noted after administration of the nutritional product.
Meanwhile, compared with the control, changes from baseline in the levels of albumin
and weight were significant after the nutritional therapy rich in ω3 fatty
acids (P few effects on
motor functions and activities of daily living in PD patients with weight loss,
but it is expected to offer effective ghrelin-mediated nutritional improvement.